SEGMENTS |
SEGMENTS We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical and genomics laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes. Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | For the three months ended September 30, | | For the nine months ended September 30, | (In thousands) | 2022 | | 2021 | | 2022 | | 2021 | Revenue from services: | | | | | | | | Pharmaceutical | $ | — | | | $ | — | | | $ | — | | | $ | — | | Diagnostics | 142,856 | | | 340,163 | | | 616,259 | | | 1,244,312 | | Corporate | — | | | — | | | — | | | — | | | $ | 142,856 | | | $ | 340,163 | | | $ | 616,259 | | | $ | 1,244,312 | | Revenue from products: | | | | | | | | Pharmaceutical | $ | 32,388 | | | $ | 36,882 | | | $ | 104,938 | | | $ | 106,490 | | Diagnostics | — | | | — | | | — | | | — | | Corporate | — | | | — | | | — | | | — | | | $ | 32,388 | | | $ | 36,882 | | | $ | 104,938 | | | $ | 106,490 | | Revenue from transfer of intellectual property and other: | | | | | | | | Pharmaceutical | $ | 4,500 | | | $ | 8,768 | | | $ | 97,659 | | | $ | 22,585 | | Diagnostics | — | | | — | | | — | | | — | | Corporate | — | | | — | | | — | | | — | | | $ | 4,500 | | | $ | 8,768 | | | $ | 97,659 | | | $ | 22,585 | | Operating income (loss): | | | | | | | | Pharmaceutical | $ | (28,298) | | | $ | 28,625 | | | $ | 9,020 | | | $ | (4,251) | | Diagnostics | (49,454) | | | 19,658 | | | (150,537) | | | 116,670 | | Corporate | (10,068) | | | (10,457) | | | (29,467) | | | (30,585) | | | | | | | | | | | $ | (87,820) | | | $ | 37,826 | | | $ | (170,984) | | | $ | 81,834 | | Depreciation and amortization: | | | | | | | | Pharmaceutical | $ | 17,840 | | | $ | 6,080 | | | $ | 50,882 | | | $ | 20,500 | | Diagnostics | 10,155 | | | 12,883 | | | 31,313 | | | 39,025 | | Corporate | — | | | — | | | — | | | — | | | $ | 27,995 | | | $ | 18,963 | | | $ | 82,195 | | | $ | 59,525 | | Loss from investment in investees: | | | | | | | | Pharmaceutical | $ | (43) | | | $ | (53) | | | $ | (359) | | | $ | (163) | | Diagnostics | — | | | — | | | — | | | — | | Corporate | — | | | — | | | — | | | — | | | $ | (43) | | | $ | (53) | | | $ | (359) | | | $ | (163) | | Revenues: | | | | | | | | United States | $ | 149,841 | | | $ | 354,586 | | | $ | 634,754 | | | $ | 1,269,749 | | Ireland | 6,680 | | | 5,445 | | | 104,318 | | | 24,663 | | Chile | 14,347 | | | 16,486 | | | 46,490 | | | 49,294 | | Spain | 4,564 | | | 5,721 | | | 17,370 | | | 17,077 | | Israel | 251 | | | 307 | | | 3,663 | | | 3,543 | | Mexico | 3,886 | | | 3,162 | | | 11,691 | | | 8,619 | | Other | 174 | | | 106 | | | 570 | | | 442 | | | $ | 179,744 | | | $ | 385,813 | | | $ | 818,856 | | | $ | 1,373,387 | |
| | | | | | | | | | | | (In thousands) | September 30, 2022 | | December 31, 2021 | Assets: | | | | Pharmaceutical | $ | 1,297,347 | | | $ | 1,114,460 | | Diagnostics | 697,118 | | | 1,238,583 | | Corporate | 230,320 | | | 46,672 | | | $ | 2,224,785 | | | $ | 2,399,715 | | Goodwill: | | | | Pharmaceutical | $ | 290,474 | | | $ | 237,576 | | Diagnostics | 283,025 | | | 283,025 | | | | | | | $ | 573,499 | | | $ | 520,601 | | No customer represented more than 10% of our total consolidated revenue during the nine months ended September 30, 2022 and 2021. As of September 30, 2022 and December 31, 2021, no customer represented more than 10% of our accounts receivable balance.
|